Literature DB >> 10913393

Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years.

K M Miernyk1, A J Parkinson, K M Rudolph, K M Petersen, L R Bulkow, D P Greenberg, J I Ward, G Brenneman, R Reid, M Santosham.   

Abstract

High rates of invasive pneumococcal disease have been described among infants living in various Native American communities. In this study, we evaluated the immunogenicity of a 7-valent pneumococcal vaccine consisting of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F covalently linked to the outer membrane protein complex of Neisseria meningitidis in Apache and Navajo Indian, Alaska Native, and non-Native American children. The vaccine was administered at ages 2, 4, and 6 months; a booster dose was given at age 15 months. Levels of serotype-specific immunoglobulin G (IgG) were measured by a standardized enzyme-linked immunosorbent assay. The responses after 3 primary doses of vaccine were similar in all 3 groups of children, except for those to serotypes 14 and 23F. One month after the booster dose, geometric mean concentrations (GMCs) of serotype-specific IgG antibodies increased significantly in all 3 groups of children, compared with GMCs of IgG antibodies to pneumococcal serotypes before the booster dose.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913393     DOI: 10.1086/313907

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

Review 1.  New pneumococcal vaccines for children.

Authors:  S Choo; A Finn
Journal:  Arch Dis Child       Date:  2001-04       Impact factor: 3.791

Review 2.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

Review 3.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: Recommendations and expected benefits.

Authors:  Carol A McClure; Michael W Ford; Jeff B Wilson; Jeff J Aramini
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-01       Impact factor: 2.471

5.  Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.

Authors:  Selma Tobudic; Veronika Plunger; Gere Sunder-Plassmann; Markus Riegersperger; Heinz Burgmann
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

Review 6.  Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.

Authors:  Maria Deloria Knoll; Daniel E Park; T Scott Johnson; Subash Chandir; Bareng Aletta S Nonyane; Laura Conklin; Katherine E Fleming-Dutra; Jennifer D Loo; David Goldblatt; Cynthia G Whitney; Katherine L O'Brien
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

7.  Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine.

Authors:  Adebayo K Akinsola; Martin O C Ota; Godwin C Enwere; Brown J Okoko; Syed M A Zaman; Mark Saaka; Ekpedeme D Nsekpong; Aderonke A Odutola; Brian M Greenwood; Felicity T Cutts; Richard A Adegbola
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

8.  Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein--conjugated pneumococcal vaccine in Filipino infants.

Authors:  Maria Z Rosario Capeding; Taneli Puumalainen; Connie P Gepanayao; Helena Käyhty; Marilla G Lucero; Hanna Nohynek
Journal:  BMC Infect Dis       Date:  2003-08-10       Impact factor: 3.090

Review 9.  Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review.

Authors:  R K Lucinde; G Ong'ayo; C Houlihan; C Bottomley; D Goldblatt; J A G Scott; K E Gallagher
Journal:  Vaccine       Date:  2021-07-31       Impact factor: 4.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.